1.According to NAVIGATOR and other trials， IGT has a very high prevalence in patients with known CV diseases or CV risks. As NAVIGATOR study has shown， Valsartan has beneficial impact on the development of NOD in IGT patients. What do you think this result will infect on the strategy to treat hypertension patients with glucose metabolic disorder?

    从NAVIGATOR筛查人群和其他调查中，可以看到在心血管病患者和具有心血管病危险的人群中，IGT的比例很高。NAVIGATOR研究提示代文能显著减少IGT转化为糖尿病，这个结果对合并有糖代谢异常的高血压患者选择药物有什么影响呢？

     2.Diabetes and hypertension are huge economic and health burdens. So from the view of pharmacoeconomics and disease prevention， what is the implication of NAVIGATOR findings for the management of hypertensive patients with IGT?

    全球共同面对着日益增长的疾病带来的经济负担，因此，从药物经济学角度以及疾病预防角度来说，NAVIGATOR研究对于高血压伴IGT患者 的管理有怎样的意义？  

     3.IGT has becoming more and more prevalent both in China and in the world. Do you think our clinical doctors pay enough attention on the treatment of IGT in hypertensive patients? Do you think NAVIGATOR study will help cardiologists to evaluate more thoroughly about CV risk factors in hypertensive patients and take best strategy available?

     您认为目前临床实践中对高血压合并IGT的现状是否有足够重视？NAVIGATOR研究结果是否能推动心内科医生能更全面评估高血压患者的心血管危险并采取最佳治疗措施？